Daily Medication Pearl: Ibrexafungerp (BREXAFEMME) for Vulvovaginal Candidiasis

Medication Pearl of the Day: Ibrexafungerp (BREXAFEMME)

Indication: Ibrexafungerp is a triterpenoid antifungal indicated for the treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis.

Insight:

• Dosing: The recommended dosage of ibrexafungerp in adult and post-menarchal pediatric females is 300 mg (2 tablets of 150 mg) twice a day for 1 day, for a total treatment dosage of 600 mg.
• Dosage form: Tablets 150 mg.
• Adverse events (AEs): The most frequent AEs associated with this drug are diarrhea, nausea, abdominal pain, dizziness, and vomiting.
• Mechanism of action: Ibrexafungerp is a triterpenoid antifungal drug.
• Manufacturer: Scynexis

Sources:

• Brexafemme 8.5 x 11 PI R2.indd (d1io3yog0oux5.cloudfront.net)
• BREXAFEMME® (ibrexafungerp, 150 mg per tablet) | Patient Information | Savings | Healthcare Professionals